Sorafenat Tablets 200 mg

Product Description

Cancer patients can use the 200 mg Sorafenat Tablets. The active ingredient in the pills is sorafenib, a targeted medication that slows angiogenesis (the creation of blood vessels) and tumour growth in specific cancers. Hepatocellular carcinoma and advanced kidney cancer (renal cell carcinoma) are both treated with sorafenat. It functions by obstructing particular proteins that encourage the growth and spread of cancer cells. In certain individuals, treatment with Sorafenat 200 mg can help delay the spread of malignant malignancies and increase overall survival. However, it could also result in negative side effects like diarrhoea, weariness, hypertension, and hand-foot skin response. While using this drug, patients should be closely watched by their doctor.

Features and Advantages of Sorafenat 200 mg Tablets:

Features:

1. Sorafenat Tablets 200 mg belong to a class of medications used in targeted therapy that specifically inhibit certain proteins involved in the proliferation and angiogenesis of cancer cells, slowing the evolution of tumours.

2. Oral Administration: Sorafenat is accessible in tablets, making it simple and convenient to administer orally. This makes it more patient-friendly than intravenous therapies.

3. Dual Indication: Hepatocellular carcinoma and advanced renal cell carcinoma are two difficult cancer forms for which Sorafenat Tablets 200 mg are approved.

Benefits:

1. Prolonged Survival: In some patients with advanced kidney and liver cancer, treatment with sorafenat can increase overall survival and progression-free survival.

2. Tumour Growth Inhibition: The drug's method of action works to reduce the size and spread of cancer cells by slowing down tumour growth.

3. Delay in Disease Progression: Sorafenat may help delay the onset of certain diseases, giving doctors and patients more time to consider alternative treatments or enhance their quality of life.

4. Sorafenat has the potential to be utilised in combination with other cancer therapies, giving patients access to more therapeutic alternatives.

5. Outpatient Care: Because Sorafenat is an oral drug, patients can receive care outside of the hospital, which is more convenient and cuts down on the number of trips.

It's critical for patients to fully grasp the dangers and potential side effects of Sorafenat Tablets 200 mg and to properly go through treatment options with their healthcare professional. The greatest outcomes during Sorafenat cancer treatment depend on regular monitoring and communication with the medical team.

Sorafenat 200 mg tablets are used for:

1. Sorafenat is used to treat advanced kidney cancer (renal cell carcinoma) that has migrated to other body parts or that cannot be removed with surgery.

2. Sorafenat is given for the treatment of advanced liver cancer (hepatocellular carcinoma), which cannot be cured surgically.

200 mg Sorafenat tablet side effects include:

1. Skin Reaction on the Hands and Feet: Patients may report soreness, swelling, and redness on the palms and soles of their hands and feet.

2. Sorafenat can induce diarrhoea, which in certain situations may be severe.

3. Patient fatigue and weakness are possible side effects of this medicine.

4. Hypertension: Some people's blood pressure levels may rise as a result of sorafenat.

5. Skin Rash: While receiving treatment, some patients may get a skin rash.

6. Sorafenat may result in gastrointestinal problems that cause nausea and vomiting.

7. Loss of Appetite: Some people may feel less hungry than usual.

8. Hair Loss: Hair loss (alopecia) or thinning hair may happen.

9. Bruising or bleeding may occur more frequently than usual while taking sorafenat.

10. Rarely, the medication may result in liver issues, which in some instances can be very serious.

11. Sorafenat may prevent wounds from healing properly following surgery.

Any severe or enduring side effects should be immediately reported by patients to their healthcare physician. Only a trained healthcare practitioner should administer Sorafenat Tablets 200 mg, and patients should be closely followed during the course of treatment.